medicaldialogues.in
USFDA approves Eli Lilly Omvoh for Crohn's disease
This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial results showing improved clinical remission and endoscopic healing versus placebo.
Adults with moderately to severely active Crohn's disease, patients who have failed or lost response to other therapies, clinicians treating IBD, and researchers following IL‑23–targeting treatments.
What To Know
The FDA has approved Omvoh (mirikizumab-mrkz) for adults with moderately to severely active Crohn's disease. The approval is based on Phase 3 VIVID-1 trial results showing higher rates of clinical remission and endoscopic response at one year versus placebo, and two-year maintenance data were highlighted.
Labeling includes standard biologic warnings (infection, tuberculosis, hypersensitivity, hepatotoxicity, immunization considerations). Lilly is pursuing additional global regulatory filings. Omvoh (mirikizumab) is an IL-23 p19–targeting biologic already approved for ulcerative colitis; this FDA decision adds Crohn's disease as an indication for adults.
The VIVID-1 randomized trial led to the approval; an open‑label extension (VIVID-2) is ongoing to assess longer-term efficacy and safety. The article summarizes company and expert statements and notes common biologic safety warnings in the US label.
If you are considering a new therapy for Crohn's disease, discuss with your gastroenterology team whether mirikizumab is appropriate for you—this article reports approval and trial results but does not replace individualized medical advice.
The article summarizes company and investigator comments and trial outcomes from the VIVID studies; it is not a detailed clinical guideline. Safety warnings are noted in the label. Ongoing open‑label studies will provide longer‑term data. Talk with your clinician about how trial populations and outcomes relate to your situation.
